Clinical trials: Round Cell Liposarcoma
Liposarcoma
Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery
This phase II trial studies how well efatutazone dihydrochloride works in treating patients with previously treated myxoid liposarcoma that cannot be removed by surgery.
- Trial name
- NCT02249949
- Testing
- efatutazone
- Where
- 127 sites in United States
- Volunteers
- 15 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug with surgery and/or radiation therapy may kill more tumor cells.
- Trial name
- NCT00002898
- Testing
- dactinomycin, carboplatin, cyclophosphamide
- Where
- United Kingdom
- Volunteers
- 400 people
- Sponsor
- Societe Internationale d'Oncologie Pediatrique
Leiomyosarcoma, Liposarcoma
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
This study will evaluate the safety and efficacy of MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment in patients with advanced soft tissue sarcoma.
- Conditions
- Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Angiosarcoma
- Trial name
- NCT06277154
- Testing
- MASCT-I, Doxorubicin, Ifosfamide
- Where
- China
- Volunteers
- 148 people
- Sponsor
- HRYZ Biotech Co.
Ovarian Cancer, Sarcoma
Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Ovarian Cancer, Sarcoma, Small Intestine Cancer
- Trial name
- NCT00025441
- Testing
- dactinomycin, filgrastim, carboplatin
- Where
- 22 sites in France, Ireland and 1 more
- Sponsor
- Societe Internationale d'Oncologie Pediatrique
Neoplasms
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.
- Trial name
- IGNYTE-ESO (NCT03967223)
- Testing
- Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide
- Where
- 38 sites in United States, Canada and 5 more
- Volunteers
- 103 people
- Sponsor
- USWM CT, LLC
Myxoid Liposarcoma, Round Cell Liposarcoma
Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
This research trial studies the immune changes following trabectedin in patients with sarcoma that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable).
- Conditions
- Myxoid Liposarcoma, Round Cell Liposarcoma, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7
- Trial name
- NCT03397186
- Testing
- Biopsy, Laboratory Biomarker Analysis, Trabectedin
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Metastatic Myxoid Liposarcoma, Metastatic Synovial Sarcoma
Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers
This phase II trial studies how well brenetafusp (IMC-F106C) works in treating patients with preferentially expressed antigen of melanoma (PRAME) positive synovial sarcoma and myxoid/round cell liposarcoma that has spread from…
- Conditions
- Metastatic Myxoid Liposarcoma, Metastatic Synovial Sarcoma, Unresectable Myxoid Liposarcoma, Unresectable Synovial Sarcoma
- Trial name
- NCT07686367
- Testing
- Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C, Biopsy Procedure, Biospecimen Collection
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma, Myxoid/Round Cell Liposarcoma
Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)
This is an open-label Phase 2 randomized study that will examine the use of the study agents, CMB305 (sequentially administered LV305 which is a dendritic cell-targeting viral vector expressing the New York Esophageal Squamous…
- Conditions
- Sarcoma, Myxoid/Round Cell Liposarcoma, Synovial Sarcoma, Metastatic Sarcoma
- Trial name
- NCT02609984
- Testing
- CMB305, atezolizumab
- Where
- 18 sites in United States
- Volunteers
- 89 people
- Sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Liposarcoma, Myxoid, Sarcoma, Soft Tissue
Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
Phase I-II trial that combines trabectedin plus radiotherapy for tumor reduction response measure in four cohorts of patients: Cohort A: Patients with diagnosis of non-operable or unresectable or not oncologically recommended…
- Conditions
- Liposarcoma, Myxoid, Sarcoma, Soft Tissue, Leiomyosarcoma, Liposarcoma
- Trial name
- TRASTS (NCT02275286)
- Testing
- Trabectedin, Radiotherapy
- Where
- 17 sites in France, Italy and 1 more
- Volunteers
- 199 people
- Sponsor
- Grupo Espanol de Investigacion en Sarcomas
Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT00474994
- Testing
- sunitinib malate
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Myxoid Liposarcoma, Round Cell Liposarcoma
N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy
This early phase I trial tests the safety and how well N-803 works in treating patients with synovial sarcoma (SS) or myxoid/round cell liposarcoma (MRCL) that is growing, spreading, or getting worse (progressive) after being…
- Conditions
- Myxoid Liposarcoma, Round Cell Liposarcoma, Synovial Sarcoma
- Trial name
- NCT07261657
- Testing
- Biospecimen Collection, Computed Tomography, Leukapheresis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Seth Pollack
Soft Tissue Sarcomas, Angiosarcoma
IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
This study will enroll patients with specific subtypes of unresectable or metastatic soft tissue sarcoma, and will combine tislelizumab with the standard chemotherapy of liposomal doxorubicin and ifosfamide to initially explore…
- Conditions
- Soft Tissue Sarcomas, Angiosarcoma, Fibrosarcoma, Leiomyosarcoma
- Trial name
- TAIS (NCT06849986)
- Testing
- Tislelizumab+liposomal doxorubicin+ifosfamide
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Fudan University
Liposarcoma, Recurrent Liposarcoma
BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma
This study is testing two different doses of BTX-A51 to determine if it is safe and tolerable in participants with liposarcoma with MDM2 amplification, myxoid liposarcoma, and CIC-rearranged sarcoma.
- Conditions
- Liposarcoma, Recurrent Liposarcoma, Metastatic Liposarcoma, Unresectable Liposarcoma
- Trial name
- NCT06414434
- Testing
- BTX-A51
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Michael Wagner, MD
Multiple Myeloma, Melanoma
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
This is a first-in-human trial proposed to test HLA-A*0201 restricted NY-ESO-1 redirected T cells with edited endogenous T cell receptor and PD-1.
- Conditions
- Multiple Myeloma, Melanoma, Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
- Trial name
- NCT03399448
- Testing
- NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Pennsylvania
Sarcoma
Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma?
Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating "cancer cell/macrophage" hybrid cells in the peripheral blood.
- Trial name
- SAMHY SARCOME (NCT04512495)
- Testing
- Blood samples will be collected at two times :
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Institut Claudius Regaud
Neoplasms
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
This trial will evaluate the safety and efficacy of first time in human engineered T-cell therapies, in participants with advanced tumors.
- Trial name
- NCT04526509
- Testing
- GSK3901961, GSK3845097, GSK4427296
- Where
- 17 sites in United States, Australia and 4 more
- Volunteers
- 12 people
- Sponsor
- Adaptimmune
Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer
EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma
MDG1015 is a third generation TCR-T therapy product targeting NY-ESO-1/LAGE-1a armored and enhanced by the PD1-41BB costimulatory switch protein (CSP).
- Conditions
- Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer, Soft Tissue Sarcoma (STS), Myxoid Liposarcoma
- Trial name
- EPITOME-1015-I (NCT06748872)
- Testing
- Lymphodepletion, TCR-T cells (MDG1015)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Medigene AG
Liposarcomas, Dedifferentiated, Liposarcoma - Well Differentiated
A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma
The purpose of this study is to determine whether ribociclib are effective and safe in the treatment of progressive well/dedifferentiated liposarcoma (WDL/DDL).
- Conditions
- Liposarcomas, Dedifferentiated, Liposarcoma - Well Differentiated, Liposarcoma; Mixed Type, Soft-Tissue Sarcoma
- Trial name
- NCT03096912
- Testing
- Ribociclib
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Assaf-Harofeh Medical Center
Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
The goal of this clinical research study is to find a recommended dose of donated NK cells that can be given along with chemotherapy to patients with advanced cancers. The safety and effects of this therapy will also be studied.
- Trial name
- NCT06083883
- Testing
- Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Synovial Sarcoma, Myxoid Liposarcoma
Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel
The purpose of this expanded access protocol (EAP) is to provide controlled access to Afamitresgene autoleucel, suspension for intravenous infusion that does not meet the commercial release specification (NC afami-cel).
- Trial name
- NCT06617572
- Testing
- Non-conforming afamitresgene autoleucel
- Where
- 11 sites in United States
- Sponsor
- USWM CT, LLC